Peter Hutt

Peter Barton Hutt is a senior counsel in the Washington, DC law firm of Covington & Burling, specializing in Food and Drug Law. Peter served as Chief Counsel of the FDA from 1971-1975. He is the co-author of the casebook used to teach Food and Drug law throughout the country and since 1994 has taught a full course on this subject each winter term at Harvard Law School. He has served on the Boards of CV Therapeutics, Pervasis Therapeutics, and IDEC Pharmaceuticals (now Biogen) during development of Rituxan, and now serves on the boards of Moderna Therapeutics, Concert Pharmaceuticals, and Selecta Biosciences. He served on numerous advisory committees including the Advisory Committee to the Director of the National Institutes of Health (NIH), and the NIH Advisory Committee to Review the Guidelines for Recombinant DNA Research.